Aptamer:toxin conjugates that specifically target prostate tumor cells.
暂无分享,去创建一个
Andrew D Ellington | Laura A Lavery | M. Levy | A. Ellington | Ted Chu | M. Rosenblum | J. W. Marks | Matthew Levy | Michael G Rosenblum | Ted C Chu | John W Marks | Sarah Faulkner | S. Faulkner
[1] A. Rajasekaran,et al. Is prostate-specific membrane antigen a multifunctional protein? , 2005, American journal of physiology. Cell physiology.
[2] John I. Loewenstein,et al. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. , 2003, Ophthalmology.
[3] Johannes Waltenberger,et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[4] B. Hicke,et al. Escort aptamers: a delivery service for diagnosis and therapy. , 2000, The Journal of clinical investigation.
[5] Laura A Lavery,et al. Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. , 2006, Biosensors & bioelectronics.
[6] H. Schluesener,et al. Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels , 2001, The Journal of Biological Chemistry.
[7] M. Rosenblum,et al. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. , 2003, Cancer research.
[8] L. Gold,et al. High affinity ligands from in vitro selection: complex targets. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[9] Anna M Wu,et al. Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.
[10] A. Kung,et al. Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties. , 1994, The Journal of biological chemistry.
[11] M. Famulok,et al. Oligonucleotide aptamers that recognize small molecules. , 1999, Current opinion in structural biology.
[12] M. Rosenblum,et al. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin , 1999, Cancer Chemotherapy and Pharmacology.
[13] B. Sullenger,et al. Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.
[14] S. Jayasena. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.
[15] Bertrand Tavitian,et al. Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase , 2005, PLoS biology.
[16] L. Gold,et al. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] B. Sullenger,et al. RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.
[18] Amy C Yan,et al. Aptamers: prospects in therapeutics and biomedicine. , 2005, Frontiers in bioscience : a journal and virtual library.
[19] D. S. Coffey,et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.